Effects of glucagon administration on microcirculation and blood rheology. 1997

R Komatsu, and N Tsushima, and T Matsuyama
Department of Internal Medicine, National Cardiovascular Center Hospital, Suita, Osaka, Japan.

It has been reported that some rheologic abnormalities are associated with diabetes. However, it is difficult to realize the condition of microcirculation in men. We developed an intra-vital video-microscopic system (IVVMS) to observe microcirculation directly on the bulbar conjunctiva. Using this system, we investigated the effect of intravenous glucagon administration on microcirculatory parameters such as the internal diameter of venules, flow velocity and flow volumes in diabetic patients. Blood viscosity and rheology factors were also examined before and after glucagon administration. The time required for erythrocytes to pass through pores of 5 microm diameter, as well as whole blood viscosity were decreased significantly after glucagon administration. Flow volumes of venules were increased significantly by glucagon. Leukocyte counts, platelet counts and fibrinogen did not change after glucagon administration. However, plasma glucose, insulin, C-peptide and cyclic-AMP were increased. In conclusion, glucagon administration improved blood fluidity and modified the microcirculation in patients with diabetes mellitus.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D001779 Blood Coagulation Factors Endogenous substances, usually proteins, that are involved in the blood coagulation process. Clotting Factor,Coagulation Factors,Blood Coagulation Factor,Clotting Factors,Coagulation Factor,Coagulation Factor, Blood,Coagulation Factors, Blood,Factor, Coagulation,Factors, Coagulation,Factor, Blood Coagulation,Factor, Clotting,Factors, Blood Coagulation,Factors, Clotting
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001809 Blood Viscosity The internal resistance of the BLOOD to shear forces. The in vitro measure of whole blood viscosity is of limited clinical utility because it bears little relationship to the actual viscosity within the circulation, but an increase in the viscosity of circulating blood can contribute to morbidity in patients suffering from disorders such as SICKLE CELL ANEMIA and POLYCYTHEMIA. Blood Viscosities,Viscosities, Blood,Viscosity, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide

Related Publications

R Komatsu, and N Tsushima, and T Matsuyama
January 1981, La Ricerca in clinica e in laboratorio,
R Komatsu, and N Tsushima, and T Matsuyama
January 1981, La Ricerca in clinica e in laboratorio,
R Komatsu, and N Tsushima, and T Matsuyama
November 1974, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
R Komatsu, and N Tsushima, and T Matsuyama
January 1990, Deutsche medizinische Wochenschrift (1946),
R Komatsu, and N Tsushima, and T Matsuyama
March 1993, Journal of biomedical engineering,
R Komatsu, and N Tsushima, and T Matsuyama
March 1963, Journal of applied physiology,
R Komatsu, and N Tsushima, and T Matsuyama
February 1994, Presse medicale (Paris, France : 1983),
R Komatsu, and N Tsushima, and T Matsuyama
January 1965, Bibliotheca anatomica,
R Komatsu, and N Tsushima, and T Matsuyama
January 1965, Bibliotheca anatomica,
R Komatsu, and N Tsushima, and T Matsuyama
December 2007, Osaka city medical journal,
Copied contents to your clipboard!